Swedish
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
cachexia/inflammation
Länken sparas på Urklipp
Sida 1 från 164 resultat
N-substituted-(Dihydroxyboryl)alkyl purine, indole and pyrimidine derivatives, useful as inhibitors of inflammatory cytokines
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
Tumor necrosis factor alpha (TNF-.alpha.), also known as cachectin, is a 17 kDa protein produced by neutrophils, activated lymphocytes, macrophages, NK cells, LAK cells, astrocytes, endothelial cells, smooth muscle cells, and some transformed cells. A large number of
Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
Tumor necrosis factor alpha (TNF-.alpha.), also known as cachectin, is a 17 kDa protein produced by neutrophils, activated lymphocytes, macrophages, NK cells, LAK cells, astrocytes, endothelial cells, smooth muscle cells, and some transformed cells. A large number of
Cyclic peptides for treatment of cachexia
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
1. Field of the Invention (Technical Field)
The present invention relates to cyclic hexapeptides that are highly-specific antagonists for the melanocortin-4 receptor (MC4-R), and which may be used in the treatment of a variety of body weight disorders including cachexia,
Cytokine suppressive anti-inflammatory drug binding protein
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF INVENTION
This invention relates to newly identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to CSBP/p38 MAP
Guanylhydrazones and their use to treat inflammatory conditions
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
1. INTRODUCTION
This invention concerns new methods and compositions that are useful in treating inflammatory conditions, e.g., preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More
Guanylhydrazones and their use to treat inflammatory conditions
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
1. INTRODUCTION
This invention concerns new methods and compositions that are useful in treating inflammatory conditions, e.g., preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More
Guanylhydrazones and their use to treat inflammatory conditions
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
TABLE OF CONTENTS
1. INTRODUCTION
2. BACKGROUND OF THE INVENTION
2.1. THE SIGNS OF CACHEXIA ARE DISTINCT FROM THOSE OF STARVATION
2.2. THE IMPLICATIONS OF THE DIFFERENCES BETWEEN CACHEXIA AND STARVATION
2.3. THE IMPACT OF THE ROLE OF CYTOKINES INCACHEXIA ON THE SEARCH FOR THERAPIES
2.4. NITRIC OXIDE
Guanylhydrazones and their use to treat inflammatory conditions
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
1. INTRODUCTION
This invention concerns new methods and compositions that are useful in treating inflammatory conditions, e.g., preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More
Guanylhydrazones and their use to treat inflammatory conditions
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
1. INTRODUCTION
2. BACKGROUND OF THE INVENTION
2.1. THE SIGNS OF CACHEXIA ARE DISTINCT FROM THOSE OF STARVATION
2.2. THE IMPLICATIONS OF THE DIFFERENCES BETWEEN CACHEXIA AND STARVATION
2.3. THE IMPACT OF THE ROLE OF CYTOKINES INCACHEXIA ON THE SEARCH FOR THERAPIES
2.4. NITRIC OXIDE AS A MEDIATOR OF
Guanylhydrazones and their use to treat inflammatory conditions
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
1. INTRODUCTION
This invent concerns new methods and compositions that are useful in treating inflammatory conditions, e.g., preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More particularly,
Guanylhydrazones and their use to treat inflammatory conditions
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
1. INTRODUCTION
This invention concerns new methods and compositions that are useful in treating inflammatory conditions, e.g., preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More
Guanylhydrazones and their use to treat inflammatory conditions
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
1. INTRODUCTION
This invention concerns new methods and compositions that are useful in treating inflammatory conditions, e.g., preventing and ameliorating cachexia, the clinical syndrome of poor nutritional status and bodily wasting associated with cancer and other chronic diseases. More
Guanylhydrazones and their use to treat inflammatory conditions
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
1. INTRODUCTION
This invention concerns new methods and compositions that are useful in treating inflammatory conditions, e.g., multiple sclerosis, rheumatoid arthritis, inflammatory bowel diseases, asthma, transplant rejection, and preventing and ameliorating cachexia, the clinical syndrome of poor
Method for treatment of cachexia by administering inhibitors of adipose triglyceride lipase expression or activity
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
FIELD OF THE INVENTION
The present invention relates to methods of prevention, treatment or alleviation of cachexia and other wasting syndromes or conditions of loss of weight and/or muscle atrophy by modulation, including inhibition, of lipase, particularly adipose triglyceride lipase (ATGL). The
Hydroxyalkylammonium-pyrimidines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines
Endast registrerade användare kan översätta artiklar
Logga in Bli medlem
BACKGROUND OF THE INVENTION
Tumor necrosis factor alpha (TNF-.alpha.), also known as cachectin, is a 17 kDa protein produced by neutrophils, activated lymphocytes, macrophages, NK cells, LAK cells, astrocytes, endothelial cells, smooth muscle cells, and some transformed cells. A large number of
Den mest kompletta databasen med medicinska örter som stöds av vetenskapen
- Fungerar på 55 språk
- Växtbaserade botemedel som stöds av vetenskap
- Örter igenkänning av bild
- Interaktiv GPS-karta - märka örter på plats (kommer snart)
- Läs vetenskapliga publikationer relaterade till din sökning
- Sök efter medicinska örter efter deras effekter
- Organisera dina intressen och håll dig uppdaterad med nyheterna, kliniska prövningar och patent
Skriv ett symptom eller en sjukdom och läs om örter som kan hjälpa, skriv en ört och se sjukdomar och symtom den används mot.
* All information baseras på publicerad vetenskaplig forskning
